Cisplatin
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Cisplatin: Drug Repurposing Evaluation — No TxGNN Predictions Available
One-Sentence Summary
Cisplatin (DB00515) is a well-established platinum-based cytotoxic chemotherapy agent, recognised as a cornerstone treatment for numerous solid tumours worldwide. The TxGNN model did not generate any repurposing predictions for this candidate in the current evidence pack (v4, data cutoff 2026-04-05), as critical input data — including mechanism of action and regulatory indication records — were not successfully retrieved. This report summarises the current data status and identifies the remediation steps required before a formal repurposing evaluation can proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not retrieved — regulatory indication records are absent from the current evidence pack |
| Predicted New Indication | Not available — TxGNN model returned no predictions |
| TxGNN Prediction Score | Not available |
| Evidence Level | Not determinable |
| Denmark Market Status | Not marketed (0 authorisations found in current dataset) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why No Prediction Is Available
The TxGNN prediction pipeline requires two foundational inputs to function: a mapped DrugBank identifier and at least one regulatory indication record. For this candidate, the DrugBank query returned a successful match (DB00515), but all downstream inputs failed:
- Mechanism of action (MOA): Not retrieved from DrugBank. This is a high-severity gap and directly prevents the mechanistic relevance analysis that underpins the model’s candidate scoring.
- Approved indication records: Zero entries were found in the Denmark regulatory dataset. Cisplatin is a globally established platinum-based chemotherapy; the absence of any authorisation record almost certainly reflects a data retrieval failure rather than a genuine absence from the Danish market. The EMA-centralised authorisation for cisplatin-containing products should be verifiable through the Laegemiddelstyrelsen product database.
- Safety warnings and contraindications: Not retrieved from the regulatory source, preventing the S1 safety pre-screening step.
Until these three gaps are resolved, no mechanistic rationale or evidence evaluation can be formally assessed.
Cytotoxicity
Based on DrugBank classification (DB00515) and established pharmacological class, Cisplatin is unambiguously an antineoplastic cytotoxic agent belonging to the platinum coordination compounds.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic — Platinum coordination compound |
| Myelosuppression Risk | High — leucopenia, thrombocytopenia, and anaemia are well-documented dose-limiting toxicities |
| Emetogenicity Classification | High — cisplatin is classified as highly emetogenic; prophylactic antiemetic therapy (5-HT₃ antagonist + NK₁ antagonist + dexamethasone) is mandatory |
| Monitoring Items | Full blood count (with differential), serum creatinine and eGFR (nephrotoxicity is a primary dose-limiting toxicity), serum electrolytes (Mg²⁺, K⁺, Na⁺, Ca²⁺), audiometry (ototoxicity monitoring), urinalysis |
| Handling Protection | Must be handled in accordance with cytotoxic drug handling regulations; requires appropriate personal protective equipment, dedicated preparation area (laminar flow cabinet), and cytotoxic waste disposal procedures |
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model could not generate repurposing predictions for Cisplatin because the two blocking data gaps — missing mechanism of action data and the absence of any regulatory indication record — prevented the pipeline from producing a scoreable candidate. No evidence table or mechanistic assessment can be completed in the current state.
To proceed, the following is needed:
- [Blocking] Retrieve approved indication, warning, and contraindication data by downloading and parsing the SmPC PDF from the Danish Medicines Agency (Laegemiddelstyrelsen) — required for S1 safety pre-screening
- [High] Query the DrugBank API directly for DB00515 to obtain the mechanism of action — required for mechanistic relevance analysis
- [High] Verify Denmark market status: Cisplatin has long been available as a standard chemotherapy across the EU; the zero-authorisation result should be investigated as a likely data retrieval issue before any regulatory conclusion is drawn
- [Follow-up] Re-run the full TxGNN prediction pipeline once complete input data is available, and re-issue this evidence pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.